The New England journal of medicine, 2020-03, Vol.382 (10), p.893-902
2020
Details
- Autor(en) / Beteiligte
- Titel
- Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
- Ist Teil von
- The New England journal of medicine, 2020-03, Vol.382 (10), p.893-902
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- Alma/SFX Local Collection
- Beschreibungen/Notizen
- Treatment options for highly drug-resistant tuberculosis are limited. In this study in South Africa, a new agent, pretomanid, was combined with bedaquiline and linezolid for a 26-week course to treat extensively drug-resistant and complicated multidrug-resistant pulmonary TB. Although there were toxic effects, 90% of patients had favorable outcomes.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1901814Titel-ID: cdi_proquest_journals_2371543053
- Format
- –
- Schlagworte
- Administration, Oral, Adolescent, Adult, Antitubercular Agents - administration & dosage, Antitubercular Agents - adverse effects, Bacterial infections, Bacterial Load, Bactericidal activity, Complications and side effects, Diarylquinolines - administration & dosage, Diarylquinolines - adverse effects, Drug dosages, Drug resistance, Drug therapy, Drug Therapy, Combination, Enrollments, Extensively drug-resistant tuberculosis, Extensively Drug-Resistant Tuberculosis - drug therapy, Extensively Drug-Resistant Tuberculosis - mortality, FDA approval, Female, Humans, Intention to Treat Analysis, Laboratories, Linezolid, Linezolid - administration & dosage, Linezolid - adverse effects, Male, Middle Aged, Multidrug resistance, Mycobacterium tuberculosis - isolation & purification, Myelosuppression, Nitroimidazoles, Nitroimidazoles - administration & dosage, Nitroimidazoles - adverse effects, Oral administration, Patient outcomes, Patients, Peripheral neuropathy, Protein synthesis, Pulmonary tuberculosis, Safety, Testing, Treatment Outcome, Tuberculosis, Tuberculosis, Multidrug-Resistant - drug therapy, Tuberculosis, Pulmonary - drug therapy, Young Adult